Clinical trial readout dates for Enliven Therapeutics Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
The next expected readout is December 2028.
Next readoutDecember 2028in ~25 months
Upcoming readouts11 Phase 3
Market cap$3.2B
Cash & investments$884M~32 quarters at last loss rate
Enliven Therapeutics Inc. reported $884M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $28M; at that rate the cash would last about 32 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
Recent SEC filings
8-KResults of Operations — earnings, may carry pipeline updates